Evidence map›Paper›PMID 28989978›Full record

ArticleNPJ precision oncology2017

The therapeutic potential of resveratrol: a review of clinical trials.

Adi Y Berman, Rachel A Motechin, Maia Y Wiesenfeld, Marina K Holz

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04317287 (A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy), which is not on this map. Cited by 388 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
388citing papers in PubMed, 7 pooled it
42.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04317287 naterminatednot on this mapstarted 2019, after this paper: background citation

A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy

TypeinterventionalSponsorSupplement Formulators, Inc.Ran2019 to 2021Enrolled9ConditionsOxidized Low Density LipoproteinArmsCardio formulation, Placebo
3 · Its place in the literature

Who cites it

388 citing papers in PubMed, 7 syntheses or guidelines pooled it, 836 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. The Green Path to Liver Health: Herbal Solutions for Non-alcoholic Steatohepatitis.Cardiovascular & hematological disorders drug targets · 2025
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  17. Review
  18. Review
  19. Article
  20. Article

328 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Adi Y BermanDepartment of Biology, Yeshiva University, New York, NY, USA.
Rachel A MotechinDepartment of Biology, Yeshiva University, New York, NY, USA.
Maia Y WiesenfeldDepartment of Biology, Yeshiva University, New York, NY, USA.
Marina K HolzDepartment of Biology, Yeshiva University, New York, NY, USA.
Yeshiva University · US

Funding

The role of the mTOR signaling pathway in ER-positive breast cancerR15CA151112 · NCI · YESHIVA UNIVERSITY · PI HOLZ, MARINA K · 2010 to 2013
$951k
Targeting Estrogen Related Receptor alpha in triple negative breast cancerR15CA220021 · NCI · YESHIVA UNIVERSITY · PI ALAYEV, ANYA · 2017 to 2017
$501k
NCI NIH HHS R15 CA151112NCI NIH HHS R15 CA220021
6 · The paper itself

Abstract

Resveratrol is a nutraceutical with several therapeutic effects. It has been shown to mimic effects of caloric restriction, exert anti-inflammatory and anti-oxidative effects, and affect the initiation and progression of many diseases through several mechanisms. While there is a wealth of in vitro and in vivo evidence that resveratrol could be a promising therapeutic agent, clinical trials must confirm its potential. In this work, we reviewed the current clinical data available regarding the pharmacological action of resveratrol. Most of the clinical trials of resveratrol have focused on cancer, neurological disorders, cardiovascular diseases, diabetes, non-alcoholic fatty liver disease (NAFLD), and obesity. We found that for neurological disorders, cardiovascular diseases, and diabetes, the current clinical trials show that resveratrol was well tolerated and beneficially influenced disease biomarkers. However resveratrol had ambiguous and sometimes even detrimental effects in certain types of cancers and in NAFLD. In most of the clinical trials, the major obstacle presented was resveratrol's poor bioavailability. Thus, this work provides useful considerations for the planning and design of future pre-clinical and clinical research on resveratrol.

Identifiers

PMID28989978
PMCPMC5630227
OpenAlexW2756041018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.